Objective: Surgical treatment of brainstem cavernous malformations (CMs) is challenging. Surgery using the endoscopic transsphenoidal transclival approach (eTSTCA) is reported as a useful alternative for ventral brainstem CMs. However, CMs located in the ventral midline of the brainstem are rare, and only a small number of case reports on these CMs treated with the eTSTCA exist. The efficacy and safety of the eTSTCA have not yet been fully examined.
Methods: A retrospective analysis was performed for 5 consecutive patients who underwent surgery via the eTSTCA for treating ventral pontine CMs.
Results: The average maximum CM diameter was 26.0 mm (18-38 mm). All patients underwent MR-diffusion tensor imaging, which confirmed that the corticospinal tract (CST) deviated posteriorly or laterally to the CM. Direct brainstem cortical stimulation was performed to localize the CST before making the cortical incision. After the excision of the CM, the cavity was filled with artificial CSF to make an aqueous surgical field (wet-field technique) for observing the tumor cavity and confirming complete hemostasis and resection. Total removal was achieved in all patients. The preoperative modified Rankin Scale score was 3 in 3 patients and 4 in 2 patients, whereas it was 1 in 2 patients and 0 in 3 patients 3 months after surgery. Postoperative CSF leakage was observed in 1 patient, and transient abducens nerve palsy was observed in 1 patient. No other intra- or postoperative complications were observed.
Conclusions: MR-diffusion tensor imaging and direct brainstem cortical stimulation were useful to ascertain the proximity of the CST to the CM. The endoscope provides a clear view even underwater, and it was safe and effective to observe the entire CM cavity and confirm complete hemostasis without additional retraction of the brainstem parenchyma, including the CST. The eTSTCA provides a direct access point to the lesion and may be a safer alternative treatment for patients whose CST deviates laterally or posteriorly to the CM.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3171/2023.6.JNS23324 | DOI Listing |
Background: Alzheimer's disease (AD) is characterized by progressive atrophy of the cerebral cortex and hippocampus, with concomitant increase in ventricular volume. Lomecel-B is a novel cell-based therapeutic approach to AD that targets neuroinflammation, microvascular dysfunction, and has the potential to stimulate endogenous tissue regeneration. We conducted MRI analysis of brain morphology in the CLEAR-MIND study, a 49-patient proof-of-concept study that tested 3 different dosing regimens of Lomecel-B vs placebo in patients with mild AD dementia.
View Article and Find Full Text PDFBackground: Alzheimer's disease (AD) is characterized by hallmark amyloid plaques and neurofibrillary tangles as well as by a significant loss of myelin in the cerebral cortex and other brain regions, which contributes to neurodegeneration and cognitive decline. Remyelination, of the myelin sheath by oligodendrocytes, is a process that may be impaired in neurodegenerative diseases. Depending on the severity of the disease, there occurs loss or partial damage of the myelin sheath surrounding the neuron leading to memory deficits.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Chungnam National University Hospital, Daejeon, Korea, Republic of (South).
Background: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive emerging tool to modulate brain activities and functional connectivity in various neuropsychiatric disorders. rTMS combined with cognitive training (rTMS-COG) has been showing cognitive enhancing effects compared to those of placebo in mild Alzheimer's disease (AD) in some previous studies. However, there is not much research to conclude how much each rTMS or COG contributes to therapeutic cognitive effects.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Hinda and Arthur Marcus Institute for Aging Research at Hebrew SeniorLife, Boston, MA, USA.
Background: Alzheimer's disease (AD) affects over 55 million people worldwide and is characterized by abnormal deposition of amyloid-β and tau in the brain causing neuronal damage and disrupting transmission within brain circuits. Episodic memory loss, executive deficits, and depression are common symptoms arising from altered function in spatially distinct brain circuits that greatly contribute to disability. Transcranial electrical stimulation (tES) can target these circuits and has shown promise to relieve specific symptoms.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Medical University of South Carolina, Charleston, SC, USA.
Background: Repetitive transcranial magnetic stimulation enhances cognition in people with mild cognitive impairment (MCI). Whereas conventional treatment requires daily sessions for 4-6 weeks, accelerated intermittent theta burst stimulation (iTBS) shortens the treatment course to just 3 days, substantially improving feasibility of use in people with MCI. We conducted a Phase I safety and feasibility trial of iTBS in MCI, finding preliminary evidence of cognitive improvement.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!